AstraZeneca (LSE: AZN) said today it has decided to discontinue the STABILIZE-CKD and DIALIZE-Outcomes Phase III evidence trials for Lokelma (sodium zirconium cyclosilicate).
AstraZeneca explained that the decision was made due to substantially increased enrolment timelines and low event rates, respectively, which made it prohibitive to deliver study results within a timeframe to meaningfully advance clinical practice.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.